Literature DB >> 10443702

Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts.

J C Reubi1, J A Laissue, B Waser, D L Steffen, R W Hipkin, A Schonbrunn.   

Abstract

The cellular distribution of the somatostatin sst2A receptor protein was investigated in the lymphatic, smooth muscular, and nervous components of the human gastrointestinal tract using subtype-specific antibody R2-88 for immunohistochemical staining of cryostat and formalin-fixed, paraffin-embedded tissue sections. Germinal centers of intestinal lymphatic follicles were immunostained, exhibiting a predominantly plasma membrane localization of the receptor. Similarly, nerve fibers and cells in the submucosal and myenteric plexus were stained for sst2A. Antibody preabsorption with 100 nmol/L antigen peptide abolished staining in all of these tissues, and immunohistochemical staining correlated with the labeling observed after receptor autoradiography using the sst2-preferring radioligand 125I-[Tyr3]octreotide. Cytoplasmic immunostaining was detected in gastrointestinal smooth muscle cells and was inhibited by antibody pre-absorption with antigen peptide. However, 125I-[Tyr3]octreotide autoradiography was negative, and Western blots showed no band at the usual 70-90 kDa location for sst2A. Instead, a band was observed at 205 kDa. This band comigrated with the rabbit myosin standard, which was also stained with R2-88, although antibody sensitivity for myosin was less than 0.002% of that for the sst2A receptor. Rigorous computer-based sequence analysis demonstrated the peptide sequence chosen for antibody production was unique. Moreover, standard sequence alignment protocols were unable to identify the sequences in myosin responsible for the observed reactivity with the R2-88 antiserum. The observed cross-reactivity emphasizes the need for extensive controls to prove the specificity of immunostaining for such low abundance proteins as receptors even when the peptide sequence chosen for antibody production is unique. This study demonstrates for the first time the presence of specific sst2A receptor protein by immunohistochemistry in the human gastrointestinal lymphatic and nervous components, but not in gastrointestinal circular and longitudinal smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443702     DOI: 10.1210/jcem.84.8.5878

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  SST3-selective potent peptidic somatostatin receptor antagonists.

Authors:  J C Reubi; J C Schaer; S Wenger; C Hoeger; J Erchegyi; B Waser; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

Authors:  Beatrice Waser; Renzo Cescato; Qisheng Liu; Yachu J Kao; Meike Körner; Emanuel Christ; Agnes Schonbrunn; Jean Claude Reubi
Journal:  Am J Pathol       Date:  2012-05       Impact factor: 4.307

Review 3.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

4.  Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy.

Authors:  D Ferone; R Pivonello; D J Kwekkeboom; F Gatto; P Ameri; A Colao; R R de Krijger; F Minuto; S W J Lamberts; P M van Hagen; L J Hofland
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

5.  Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.

Authors:  Jean Claude Reubi; Beatrice Waser; Renzo Cescato; Beat Gloor; Christoph Stettler; Emanuel Christ
Journal:  J Clin Endocrinol Metab       Date:  2010-03-12       Impact factor: 5.958

6.  Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting.

Authors:  Meike Körner; Beatrice Waser; Agnes Schonbrunn; Aurel Perren; Jean Claude Reubi
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

7.  Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas.

Authors:  Elaine Lu Wang; Zhi Rong Qian; Shozo Yamada; Md Mustafizur Rahman; Naoko Inosita; Teruyoshi Kageji; Hideko Endo; Eiji Kudo; Toshiaki Sano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

8.  In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.

Authors:  Regi Thomas; Jianqing Chen; Martine M Roudier; Robert L Vessella; Laura E Lantry; Adrian D Nunn
Journal:  Clin Exp Metastasis       Date:  2008-10-31       Impact factor: 5.150

9.  Cellular detection of sst2A receptors in human gastrointestinal tissue.

Authors:  M Gugger; B Waser; A Kappeler; A Schonbrunn; J C Reubi
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 10.  Illuminating somatostatin analog action at neuroendocrine tumor receptors.

Authors:  Jean Claude Reubi; Agnes Schonbrunn
Journal:  Trends Pharmacol Sci       Date:  2013-10-31       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.